ArticleJournal of orthopaedic surgery and research2026
LINC00312 affects the progression of osteoarthritis by targeting miR-331-3p/DUSP5 axis.
Article in Journal of orthopaedic surgery and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAs a chronic degenerative disease, osteoarthritis (OA) manifests through articular cartilage breakdown and ongoing inflammatory processes in joints. Recently, long non-coding RNAs (lncRNAs) have been participated in pathological process of OA through epigenetic regulation and molecular signaling axis.
aimThis study aimed to verify whether LINC00312 regulates DUSP5 expression by adsorbing miR-331-3p as a competitive endogenous RNA (ceRNA) in OA, thereby exerting a cartilage-protective effect.
methodsExpressions of LINC00312, miR-331-3p, and dual-specific protein phosphatase 5 (DUSP5) in patient tissues and chondrocytes were detected by reverse transcription-quantitative PCR (RT-qPCR). An in vitro OA model was constructed by stimulating chondrocytes with IL-1β. Cell viability and apoptosis were assessed via cell counting kit-8 (CCK-8) assays and flow cytometry. The levels of chondrogenic-related genes and proinflammatory factors were detected by RT-qPCR and enzyme-linked immunosorbent assay (ELISA). Interaction of miR-331-3p with LINC00312 and DUSP5 was detected via dual luciferase assays and RIP assays. Correlation between LINC00312, miR-331-3p, and DUSP5 in patients with OA was analyzed using Pearson correlation analysis.
resultsIn OA patients' cartilage tissue and IL-1β-induced OA models, LINC00312 and DUSP5 expression decreased while miR-331- 3p expression increased. Overexpression of LINC00312 ameliorated cell injury induced by IL-1β stimulation, enhanced cell viability, and reduced apoptosis, MMP13, ADAMTS5, IL-6, and IL-8 levels. miR-331-3p negatively correlated with LINC00312, and upregulation of miR-331-3p reversed the protective effect of LINC00312. Additionally, DUSP5 was a direct target of miR-331-3p, and LINC00312 and miR-331-3p jointly regulated DUSP5 expression.
conclusionsLINC00312 alleviates IL-1β-induced chondrocyte inflammation and apoptosis by acting as a ceRNA to regulate the miR-331-3p/DUSP5 axis. This suggests that LINC00312 may serve as a novel therapeutic target for OA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.